Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.

  • Camille Sabathé
  • Romain Casey
  • Sandra Vukusic
  • Emmanuelle Leray
  • Guillaume Mathey
  • Jérôme De Sèze
  • Jonathan Ciron
  • Sandrine Wiertlewski
  • Aurélie Ruet
  • Jean Pelletier
  • Hélène Zéphir
  • Laure Michel
  • Christine Lebrun-Frenay
  • Xavier Moisset
  • Eric Thouvenot
  • Jean-Philippe Camdessanché
  • Serge Bakchine
  • Bruno Stankoff
  • Abdullatif Al Khedr
  • Philippe Cabre
  • Elisabeth Maillart
  • Eric Berger
  • Olivier Heinzlef
  • Karolina Hankiewicz
  • Thibault Moreau
  • Olivier Gout
  • Bertrand Bourre
  • Abir Wahab
  • Pierre Labauge
  • Alexis Montcuquet
  • Gilles Defer
  • Aude Maurousset
  • Nicolas Maubeuge
  • Dalia Dimitri Boulos
  • Haïfa Ben Nasr
  • Chantal Nifle
  • Olivier Casez
  • David-Axel Laplaud
  • Yohann Foucher

Source: Mult Scler

Publié le

Résumé

BACKGROUND: In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression.

OBJECTIVE: We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy.

METHODS: Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients. We used a frailty Cox model for predicting individual hazard ratios (iHRs).

RESULTS: From the validation PS-matched cohort of 348 independent patients with iHR ⩽ 0.69, we reported the 5-year relapse-free survival at 0.14 (95% confidence interval (CI) 0.09-0.22) for the waiting group and 0.40 (95% CI 0.32-0.51) for the switched group. From the validation PS-matched cohort of 518 independent patients with iHR > 0.69, these values were 0.37 (95% CI 0.30-0.46) and 0.44 (95% CI 0.37-0.52), respectively.

CONCLUSIONS: By using the proposed dynamic score, we estimated that at least one-third of patients could benefit from an earlier switch to prevent relapse.